IPCALAB - Ipca Labs.
📢 Recent Corporate Announcements
IPCA Laboratories has informed the exchanges that the audio recording of its Q3 FY26 earnings conference call is now available. The call was conducted on February 16, 2026, to discuss the company's financial performance and business outlook for the third quarter. This disclosure is a routine regulatory requirement under SEBI (LODR) Regulations, 2015. Investors can access the recording via the company's official website to understand management's perspective on recent results.
- Audio recording of Q3 FY26 earnings call released on February 16, 2026
- Call focused on discussing the company's financial results and business updates
- Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Recording link hosted on the IPCA Laboratories official website for public access
IPCA Laboratories reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 6.5% YoY to ₹2,392.50 crore. The consolidated net profit attributable to owners surged by 31.5% to ₹326.27 crore, up from ₹248.14 crore in the same quarter last year. The company's nine-month consolidated revenue reached ₹7,257.85 crore, reflecting steady growth. Additionally, the company expanded its international footprint by acquiring 100% of Unichem Laboratories Ireland and incorporating a new subsidiary in Germany.
- Consolidated Revenue from operations increased to ₹2,392.50 Cr from ₹2,245.37 Cr YoY.
- Net Profit attributable to owners grew significantly by 31.5% YoY to ₹326.27 Cr.
- Nine-month consolidated revenue reached ₹7,257.85 Cr compared to ₹6,692.90 Cr in the previous year.
- Completed 100% acquisition of Unichem Laboratories Limited, Ireland, and established a German subsidiary.
- Standalone Profit Before Tax (PBT) for the quarter stood at ₹417.22 Cr, up from ₹355.52 Cr YoY.
IPCA Laboratories has officially commenced commercial production at its new greenfield manufacturing facility located in Wardha, Maharashtra. The facility is dedicated to the production of Drug Intermediates and Active Pharmaceutical Ingredients (APIs), representing a strategic move to enhance its manufacturing footprint. The project was completed with a total capital outlay of approximately Rs. 182 crores. This expansion is expected to strengthen the company's vertical integration and support long-term growth in the API segment.
- Commencement of commercial production at the new greenfield facility in Village Hingani, Wardha.
- Total capital expenditure for the new unit is approximately Rs. 182 crores.
- The facility focuses on manufacturing Drug Intermediates and Active Pharmaceutical Ingredients (APIs).
- The expansion aligns with IPCA's strategy to bolster its supply chain and API market presence.
IPCA Laboratories has received the Establishment Inspection Report (EIR) for its Tarapur API manufacturing facility following a US FDA inspection in December 2025. The facility has been classified as 'Voluntary Action Indicated' (VAI), indicating a minimally acceptable state of compliance with current good manufacturing practices (CGMP). This classification is a positive outcome as it typically allows for new product approvals and continued exports to the US market. The inspection was conducted between December 1 and December 5, 2025, and the EIR was received on February 7, 2026.
- US FDA inspection of Tarapur API facility conducted from Dec 1 to Dec 5, 2025
- Facility received Establishment Inspection Report (EIR) on Feb 7, 2026
- Classification assigned as Voluntary Action Indicated (VAI)
- Facility deemed in a minimally acceptable state of compliance with CGMP
IPCA Laboratories has scheduled its Q3FY26 earnings conference call for Monday, February 16, 2026, at 15:30 hrs IST. This follows the company's scheduled financial results announcement on Friday, February 13, 2026. The call will feature Managing Director Mr. A K Jain and Corporate Counsel Mr. Harish Kamath. The session aims to provide a detailed discussion on the quarterly financial performance and provide a general business update to analysts and institutional investors.
- Conference call scheduled for February 16, 2026, at 3:30 PM IST
- Q3FY26 financial results to be declared on February 13, 2026
- Management representation includes Managing Director Mr. A K Jain
- Call hosted by Dam Capital Advisors Ltd with universal dial-in numbers +91-22-6280 1384
IPCA Laboratories has filed a report regarding the re-lodgement of transfer requests for physical shares for the months ended November 30, 2025, and December 31, 2025. This disclosure is a standard compliance requirement under SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97. The report was prepared by the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited. This is a purely administrative update and does not impact the company's financial health or business operations.
- Compliance with SEBI Circular dated July 2, 2025, regarding physical share transfers.
- Covers re-lodgement requests for the periods ending November 30 and December 31, 2025.
- Report submitted by Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
- Standard regulatory filing with no material impact on company fundamentals.
Ipca Laboratories has announced the sale of its 100% stake in step-down US subsidiary, Bayshore Pharmaceuticals LLC, to Centaur Pharmaceuticals USA Inc for $400,000. Bayshore is currently an inactive entity with no assets or liabilities, following the sale of its core generic business and ANDAs to Unichem in 2024. The divestment is intended to eliminate the compliance costs of maintaining a non-operational entity in the US. Separately, the company is updating its registered office details to facilitate regulatory filings for new industrial projects.
- Divestment of 100% equity in step-down subsidiary Bayshore Pharmaceuticals LLC for a consideration of $400,000
- Bayshore is currently inactive with no assets or liabilities except a small bank balance of approximately $5,200
- The transaction is expected to be completed within 30 days of the agreement signing scheduled for January 20, 2026
- Sale is to an unrelated party, Centaur Pharmaceuticals USA Inc, and does not constitute a related party transaction
- Administrative update to registered office address to enable Industrial Entrepreneur Memorandum (IEM) filings for new projects
Ipca Laboratories has approved the sale of its 100% stake in its US-based step-down subsidiary, Bayshore Pharmaceuticals LLC, to Centaur Pharmaceuticals USA Inc. for a consideration of $400,000. Bayshore is currently an inactive entity with no significant assets or liabilities following the sale of its generic business and product approvals to Unichem in 2024. The move is intended to eliminate ongoing compliance costs for a non-operational unit. Additionally, the board approved a minor administrative update to the registered office address to facilitate new industrial project applications.
- Sale of 100% shareholding in Bayshore Pharmaceuticals LLC for a total consideration of USD 4,00,000.
- Bayshore is currently inactive with no assets or liabilities except a small bank balance of approximately USD 5,200.
- The transaction is expected to be completed within 30 days of signing the agreement, scheduled for around January 20, 2026.
- The buyer, Centaur Pharmaceuticals USA Inc., is an unrelated party and the transaction is not a related party deal.
- Administrative update to include 'Mumbai' district in the registered office address to enable IEM filings for new industrial projects.
IPCA Laboratories has filed the compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The certificate, issued by Registrar MUFG Intime India Pvt. Ltd., confirms that all securities received for dematerialization were processed within the prescribed timelines. It further verifies that physical certificates were mutilated and cancelled, and the names of depositories were updated in the register of members. This is a standard administrative filing required by all listed companies in India.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Registrar MUFG Intime India Pvt. Ltd. confirmed processing of dematerialization requests.
- Securities involved in the process are already listed on the BSE and NSE.
- Physical share certificates were mutilated and cancelled following SEBI regulatory guidelines.
The US FDA conducted an inspection of IPCA Laboratories' Active Pharmaceutical Ingredients (APIs) manufacturing facility in Tarapur (Palghar-Maharashtra) from December 1st to December 5th, 2025. Following the inspection, the US FDA issued a Form 483, which included 3 observations. IPCA Laboratories plans to submit a comprehensive response to the US FDA within the stipulated timeframe. The company is committed to resolving the issues and maintaining high standards of quality and compliance.
- US FDA inspected IPCA's API facility in Tarapur from December 1st to 5th, 2025
- US FDA issued a Form 483 with 3 observations
- IPCA will respond to US FDA within the stipulated time
Financial Performance
Revenue Growth by Segment
Formulation business for Q2 FY26 was INR 493 Cr, representing a decline of approximately 9% YoY. API business in Q2 FY26 delivered growth reaching INR 408 Cr. The chronic segment share of the business increased to 35%, while the overall market growth was 7% and Ipca's growth tracked at 11.6%.
Geographic Revenue Split
The US business showed a growth of 12% in the recent quarter. Unichem's US business contribution is approximately 60% to 65% of its total revenue. API exports account for nearly 79% of the API and Intermediates business, serving over 100 countries.
Profitability Margins
Standalone EBITDA margin improved to 25.46% in Q2 FY26 from 22.89% in Q2 FY25, a 2.57% increase. Consolidated EBITDA margin for Q2 FY26 stood at 21.68% compared to 19.1% in Q2 FY25. Gross margins for the last three quarters have stabilized around 54%.
EBITDA Margin
Consolidated EBITDA margin is 21.68% for Q2 FY26, up from 19.1% YoY. The company has provided a consolidated margin guidance of approximately 20% for the full year, with expected improvements of 1% in H2 FY26 driven by cost savings at Unichem.
Capital Expenditure
Ipca is investing in a new greenfield Drug Intermediates/Bulk Drugs manufacturing unit at Hingni. While specific total INR Cr for this project is not disclosed, the company maintains a focus on backward integration to ensure supply chain reliability.
Credit Rating & Borrowing
The company has successfully reduced debt, though specific interest rate percentages are not disclosed. Interest expenses for the standalone entity were INR 46 Cr as of March 2023.
Operational Drivers
Raw Materials
Drug Intermediates and Bulk Drugs are the primary raw materials. Material costs decreased by approximately 3% in the current quarter, contributing to a 2.57% improvement in standalone EBITDA margins.
Import Sources
Not specifically disclosed in available documents, though the company operates as a fully-integrated player with 79% of API business involving exports/imports across 100+ countries.
Capacity Expansion
Setting up a new greenfield Drug Intermediates/Bulk Drugs manufacturing unit at Hingni, Dist. Wardha. Current operations include the manufacturing of over 350 formulations and 80 APIs.
Raw Material Costs
Material costs as a percentage of revenue decreased by 3% YoY in Q2 FY26. This reduction was a primary driver for the expansion of the standalone EBITDA margin to 25.46%.
Manufacturing Efficiency
Consolidation of Unichem's European business into the Baddi facility, which already possesses necessary regulatory approvals and customer clearances, to optimize manufacturing costs.
Logistics & Distribution
The company employs 9,826 personnel specifically for marketing and distribution activities out of a total workforce of 18,043.
Strategic Growth
Expected Growth Rate
14-15%
Growth Strategy
Growth will be achieved through the integration of Unichem, filing dossiers in new markets (Australia, New Zealand, Canada), and expanding the US portfolio. The company has already shipped 6 products to the US with 6-7 more in the manufacturing pipeline. Cost optimization includes cutting EUR 3.5M-4M in European expenses by shifting production to India.
Products & Services
The company sells over 350 formulations and 80 APIs across various therapeutic segments, including acute and chronic therapies, cosmetic dermatology, and orthopedics.
Brand Portfolio
Ipca, Unichem (subsidiary). Specific product brand names are not listed, but the company is a top 20 pharmaceutical player in India.
New Products/Services
Launched a range of products in cosmetic dermatology and orthopedics. Expected revenue contribution is not quantified, but these are part of the strategy to extend the product range and improve margins.
Market Expansion
Targeting 'Rest of the World' (ROW) markets including Australia, New Zealand, and Canada through Unichem dossier filings, with a registration timeline of 12-18 months.
Market Share & Ranking
Ipca is among India’s top 20 pharmaceutical companies. Its market share in the domestic market improved from 2.3% to 2.4%.
Strategic Alliances
Acquisition and integration of Unichem Laboratories. The company also mentioned a 'handshake' agreement to transfer European business to the Baddi facility.
External Factors
Industry Trends
The industry is shifting toward chronic therapies and backward integration for APIs. Ipca is positioning itself by increasing its chronic mix to 35% and expanding its API export base (79% of API revenue).
Competitive Landscape
Faces intense competition in the US generic market, leading to price erosion and market share loss in key products. Key competitors include other top 20 Indian pharma companies.
Competitive Moat
Moat is built on deep backward integration in APIs and a strong domestic distribution network (9,800+ staff). This integration provides cost competitiveness and supply chain reliability that is difficult for non-integrated peers to replicate.
Macro Economic Sensitivity
Sensitive to currency fluctuations and changes in government tax regimes/policies in the 100+ countries where it operates.
Consumer Behavior
Increasing demand for chronic disease treatments in the Indian market, where the market share for chronic products is 40% compared to Ipca's 35%.
Geopolitical Risks
Exposure to regulatory changes in Europe and the US. The closure of a European facility resulted in a EUR 3.5M to 4M expenditure reduction but required navigating EU regulations and penalties.
Regulatory & Governance
Industry Regulations
Operations are subject to stringent regulatory approvals from international bodies for API and formulation exports. Dossier registrations for new markets like Canada and Australia take 12-18 months.
Taxation Policy Impact
Standalone tax rate was 33% in March 2023, down from 49% in March 2020.
Legal Contingencies
The company settled European Union penalties and facility closure costs in Q1 FY26, involving a provision of INR 10 Cr to INR 12 Cr.
Risk Analysis
Key Uncertainties
Regulatory involvement in new market entries creates a 2-3 year lead time for significant revenue contribution. Price erosion in generics remains a constant risk to margins.
Geographic Concentration Risk
Unichem business is heavily concentrated in the US (60-65% of its revenue). Ipca's API business is 79% export-dependent.
Third Party Dependencies
The company is moving toward 100% internal sourcing for major APIs to reduce third-party dependency, though sourcing from new internal units is pending regulatory approvals.
Credit & Counterparty Risk
Debtor days of 61 days indicate moderate credit exposure. The company maintains internal financial controls to safeguard assets.